Clinical-stage biotechnology company Novavax, Inc. (NASDAQ: NVAX) today announced that data from the second of two phase II trials of its RSV F protein recombinant nanoparticle vaccine candidate in women of childbearing age have been published in the journal Vaccine. This specific information was previously shared at scientific conferences, and top line results from this trial were originally announced in April 2014. “The Western Blot finding from this trial, which demonstrates a reduction in recent RSV infections of approximately 52% in the vaccine relative to the placebo arms, is consistent with the Western Blot data we reported from a comparable trial and population in September of 2015,” Gregory Glenn, M.D., president, research and development of Novavax, stated in the news release. “Together, these data suggest that the RSV F Vaccine provided protection against RSV infection in controlled trials of over 1,000 women.” The company’s share price recorded an increase of nearly nine percent in morning trade following the news, with its PPS sitting at $1.11 just after noon.
To view the full press release, visit http://nnw.fm/G0e4t
About Novavax
Novavax, Inc. (NASDAQ: NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company’s website, www.Novavax.com.
About NetworkNewsBreaks
NetworkNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
